^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MET expression

    i
    Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    10ms
    MET+ Expression May Be Predictive of Responses With Amivantamab/Lazertinib in Post-Osimertinib NSCLC @BenjaminBesseMD @GustaveRoussy @ASCO #ASCO23 #lcsm https://t.co/YpRja7Cdom (@OncLive)
    MET expression
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    11ms
    #ASCO23 Abs9042 #LCSM #CHRYSALIS2: Amivantamab+lazertinib in post-osimertinib, chemo-naïve EGFR-mutated advanced NSCLC. ➡️101 evaluable patients, IHC-based MET expression found predictive for response🧪. ➡️ MET+ ORR 61% (95% CI, 41–78) vs MET- ORR 12% (95% CI, 5–25) 💯. ➡️ No… https://t.co/m7yKYRbQnL (@ADesaiMD)
    Clinical • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET expression
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    almost2years
    Dr. @GRecondoMD discusses promising options in #EGFR mutant NSCLC. Phase Ib of telisotuzumab vedotin (teliso-V, MET ADC) and osimertinib for pts post osi with #MET IHC expression showed RR 58% and efficacy in high and intermediate expression. (@StephenVLiu)
    Clinical • P1 data
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • MET expression
    |
    Tagrisso (osimertinib) • telisotuzumab vedotin (ABBV-399)
    almost2years
    Hypothesis-generating: Addition of afatanib to patients c/ EGFR over-expressing met gastric cancer should be explored. Addition of IO to chemo (or in place of chemo) for periop Rx of resectable gastric cancer should be explored, esp among pts c/ MSI-H/dMMR/hPDL1CPS tumors. (@tpjmd)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • EGFR expression • EGFR overexpression • MET overexpression • MET expression
    over2years
    Dr. @alexdrilon reviews #MET in NSCLC in #PTTO2021. Capmatinib and tepotinib now approved for METex14. Resistance can be mediated by decreased expression, MET kinase domain mutations, or off target mechanisms like EGFR and KRAS. Consider type switching as a strategy! #LCSM (@StephenVLiu)
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • MET mutation • MET expression
    |
    Tepmetko (tepotinib) • Tabrecta (capmatinib)
    almost3years
    #ASCO21 In this cohort, 20 patients had tissue for IHC. Ten patients were IHC+ for EGFR/MET expression and RR to amivantamab/lazertinib was 90% with DOR 9.7m, CBR 100%, mPFS 12.5m. This is very impressive. #LCSM (@StephenVLiu)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR expression • MET expression
    |
    Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
    over3years
    MET IHC is back from the dead! We wrote it off as a biomarker, but pl see latest study from our group lead by @alexdrilon & @RobinGuo5 which found MET expression to predict TKI response in MET Ex 14-altered NSCLC. Twists & turns of the ever-evolving NSCLC biomarker story! (@natasharekhtman)
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    almost4years
    We can capture Circulating tumor cells from #kidneycancer expressing MET and CA9. Great collaborative effort w Seungpyo Hong! ⁦@DukeGUCancer⁩ ⁦@Daniel_J_George⁩ ⁦@AarmstrongDuke⁩ ⁦@andyzwang https://t.co/ZYww5mb4Ib (@TiansterZhang)
    Circulating Tumor Cells
    |
    CA9 (Carbonic anhydrase 9)
    |
    MET expression • CA9 expression